Revenue and Earnings Growth
Teleflex revenues for Q4 2024 were $795.4 million, up 2.8% year-over-year on a GAAP basis and 3.2% on an adjusted constant currency basis. Adjusted earnings per share grew 15.1% to $3.89.
Strong Performance in Interventional and Surgical Segments
The Interventional and Surgical businesses showed significant growth in the fourth quarter with adjusted constant currency growth of 18.7% and 12.3%, respectively.
Successful Cash Flow Management
Cash flow from operations increased 24.7% year-over-year to $638.3 million in 2024, compared to $511.7 million in the prior year period.
Strategic Acquisition Announcement
Teleflex announced the acquisition of BIOTRONIK's Vascular Intervention business for approximately EUR 760 million, expected to close by the end of Q3 2025.
Share Repurchase Program
A $300 million accelerated share repurchase program was announced, expected to complete the existing $500 million share repurchase program authorized in July 2024.
Separation into Two Independent Companies
Teleflex plans to separate into two independent publicly traded companies by mid-2026, with one focused on Vascular Access, Interventional, and Surgical, and the other on Urology, Acute Care, and OEM.